
Sign up to save your podcasts
Or


Send a text
This episode of the EMERGE, join me and Dr. Mike Lynch, an expert in emergency medicine, medical toxicology, and addiction medicine. The discussion delves into the public health emergency of medetomidine-related toxicity and withdrawal. Dr. Lynch shares insights from real cases, emphasizing the clinical red flags and management strategies for medetomidine withdrawal. We discuss the transition from Xylazine to medetomidine in the drug supply, the role of naloxone, and the risks of misidentifying opioid-related cases. Key points include the need for extended observation in the ED, the potential requirement for ICU care, and the effectiveness of dexmedetomidine in managing severe withdrawal symptoms. The episode also highlights the importance of medication for opioid use disorder (MOUD) and the evolving drug supply landscape.
By Mohamed Hagahmed, MD, MPH5
77 ratings
Send a text
This episode of the EMERGE, join me and Dr. Mike Lynch, an expert in emergency medicine, medical toxicology, and addiction medicine. The discussion delves into the public health emergency of medetomidine-related toxicity and withdrawal. Dr. Lynch shares insights from real cases, emphasizing the clinical red flags and management strategies for medetomidine withdrawal. We discuss the transition from Xylazine to medetomidine in the drug supply, the role of naloxone, and the risks of misidentifying opioid-related cases. Key points include the need for extended observation in the ED, the potential requirement for ICU care, and the effectiveness of dexmedetomidine in managing severe withdrawal symptoms. The episode also highlights the importance of medication for opioid use disorder (MOUD) and the evolving drug supply landscape.

14,346 Listeners

1,875 Listeners

94 Listeners

113,468 Listeners

276 Listeners

56,962 Listeners

2,841 Listeners

39 Listeners

46,354 Listeners

45 Listeners

19 Listeners

213 Listeners

9 Listeners

167 Listeners

12,351 Listeners